Why the LBT Innovations share price rocketed 243% higher on Tuesday

The LBT Innovations Limited (ASX:LBT) share price was an impressive performer on Tuesday, rising a staggering 243% at one stage…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the Australian share market on Tuesday was the LBT Innovations Limited (ASX: LBT) share price.

The medical technology company's shares finished the day a massive 136% higher at 16.5 cents but were as much as 243% higher to 24 cents at one stage.

Why did the LBT Innovations share price rocket 243% higher?

Investors were fighting to get hold of the company's shares yesterday after it announced that its 50%-owned joint venture company, Clever Culture Systems, has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its APAS Independence instrument with associated urine analysis module.

According to the release, the FDA clearance is the final regulatory milestone for the instrument, meaning Clever Culture Systems can now commence with sales in the United States.

Management believes that the APAS Independence instrument is the only commercially available instrument for the automatic reading of culture plates in the United States.

In light of this milestone being achieved, the Clever Culture Systems business will now bring forward its US commercialisation and sales activities.

What is the APAS Independence instrument?

The release explains that APAS Independence is a fully automated instrument with the ability to process over 200 culture plates per hour. This is at least three times faster than manual culture plate reading.

The instrument can differentiate culture plates showing bacterial growth from those that are not, without the need for highly skilled microbiologist assistance.

This is key to the clinical utility of the instrument that enables the instrument to be truly autonomous, and without the need for further intervention.

What is the market opportunity?

There are over 5,000 clinical laboratories in the United States, making it the single largest pathology market in the world.

Management estimates that there are more than 1,500 laboratories in this market that exceed the daily culture plate volume that would make the commercial return on investment for the purchase of an APAS Independence attractive.

Previous presentations have suggested a purchase price of ~US$300,000 for APAS Independence, which would make its target market worth around US$450 million.

Elsewhere in the medtech industry on Tuesday, the Nanosonics Ltd (ASX: NAN) share price dropped 4.5% and the Pro Medicus Limited (ASX: PME) share price fell just over 2%.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited and Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Speculative

A man balances on a tightrope across rocks above the sea at sunset.

My top high-risk, high-reward ASX shares to buy in March

If you go into it with your eyes open about the pitfalls, speculative stocks could be fine in a well…

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Ask a Fund Manager

2 'outstanding' small-cap ASX shares that could explode: expert

Ask A Fund Manager: Alto Capital's Tony Locantro reveals a pair of small caps that he reckons have a bright…

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Technology Shares

Why is the Weebit Nano share price rocketing 23% higher?

Weebit Nano shares are on fire on Wednesday...

Read more »

Man presses green buy button and red sell button on a graph.
Broker Notes

Broker names 3 speculative ASX shares to buy

Here are three speculative shares rated as buys...

Read more »

Scared looking people on a rollercoaster ride representing the volatile Mineral Resources share price in 2022
Resources Shares

May was a rollercoaster ride for the Vulcan (ASX:VUL) share price

Shareholders in the ambitious lithium producer had to fasten their seat belts last month.

Read more »

Five stacked building blocks with green arrows, indicating rising inflation or share prices
Share Gainers

The ClearVue (ASX:CPV) share price is up 65% in a month. Here's why

The ClearVue Technologies Ltd (ASX: CPV) share price is up 65% in the last month. We take a look at…

Read more »

tech shares represented by woman holding hand out to touch icons on digital screen

2 small cap ASX tech shares to buy now

Whispir Ltd (ASX:WSP) and this small cap ASX tech share could be quality options for investors after recent pullbacks...

Read more »


2 small cap ASX shares you need to know about

Nitro Software Ltd (ASX:NTO) and this small cap ASX share could be the ones you need to know about right now.…

Read more »